Grzegorz Nowakowski, MD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    AbbVie Inc.
    Date added:
    09/29/2023
    Date updated:
    09/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    ADC Therapeutics
    Date added:
    09/29/2023
    Date updated:
    09/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    TG Therapeutics, Inc
    Date added:
    09/29/2023
    Date updated:
    09/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Fate Therapeutics
    Date added:
    09/29/2023
    Date updated:
    09/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    MEI Pharma
    Date added:
    09/29/2023
    Date updated:
    09/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Incyte Corporation
    Date added:
    09/29/2023
    Date updated:
    09/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Selvita Inc
    Date added:
    09/29/2023
    Date updated:
    09/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Debiopharm
    Date added:
    09/29/2023
    Date updated:
    09/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Ryvu Therapeutics
    Date added:
    09/29/2023
    Date updated:
    09/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Celgene Corporation
    Date added:
    09/29/2023
    Date updated:
    09/29/2023

Pages

Return to Bridging Hematologic Cancer Disparities: A Path to Equity